DUSA Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference

DUSA Pharmaceuticals's picture
Printer-friendly versionPrinter-friendly versionPDF versionPDF version

For release at 8:30 a.m. 

Contact:
Chad Rubin, Investor Relations Contact, The Trout Group LLC - 646.378.2947



 

DUSA Pharmaceuticals to Present at the
14th Annual BIO CEO & Investor Conference

WILMINGTON, MASS. – February 6, 2012 — DUSA Pharmaceuticals, Inc.®  (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the 14th Annual BIO CEO & Investor Conference.  The conference is being held at the Waldorf Astoria Hotel in New York on February 13-14, 2012.  Mr. Doman is scheduled to present at 2:30 p.m. EST on February 14, 2012Interested parties can access the live audio webcast of the presentation at www.dusapharma.com. An archived version of the presentation will be available on the DUSA website approximately three hours following the presentation.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® PDT technology platform.  Levulan® Kerastick® for topical solution plus DUSA’s BLU-U® Blue Light Photodynamic Therapy Illuminator is currently approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp.  DUSA is based in Wilmington, Mass.  Please visit our website at www.dusapharma.com.

News Source : DUSA Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference

Copy this html code to your website/blog to embed this press release.